Hide metadata

dc.contributor.authorHagtvedt, Heidi Marthea Runningen
dc.date.accessioned2015-09-16T22:01:15Z
dc.date.available2015-09-16T22:01:15Z
dc.date.issued2015
dc.identifier.citationHagtvedt, Heidi Marthea Runningen. Akutt myelogen leukemi hos barn med Downs syndrom. Master thesis, University of Oslo, 2015
dc.identifier.urihttp://hdl.handle.net/10852/45987
dc.description.abstractAbstract Background: Children with Down syndrome (DS) have an increased susceptibility for acute myeloid leukaemia (AML) related to mutations in the hematopoietic transcription factor GATA1. We wanted to explore AML in these children and describe its features with regard to patient characteristics and laboratory findings at diagnosis, the course before diagnosis, treatment response and follow-up status. Material and methods: We retrospectively identified all children with Down syndrome and AML treated at Oslo University Hospital in the period 1984-2013 (n=21) and compared these to the last registered non-DS children with AML (n=21) treated in the same hospital in the period 2002-2013. Data about patient characteristics, findings, symptoms, treatment and survival was collected from patient records and the Nordic society of haematology and oncology (NOPHO) database. Results: The patients in the DS-group were younger at the time of diagnosis (median age 1 year in DS-group vs. 7 years in non-DS-group), presented with lower values of leukocytes (median value 8,9 x109/l vs. 19,4 x109/l) and thrombocytes (median value 29,5 x109/l vs. 45 x109/l), and had a predominance of megakaryocytic leukaemia (90,5% vs. 4,8%). The DS-group had a longer median delay before diagnosis (95,5 days vs. 51 days) and had more bone marrow examinations (median value 2 vs. 1). The DS-children responded better to therapy with no relapses (0% vs. 42,9%) and better overall survival (86% vs 70%). Conclusions: Acute myeloid leukaemia in Down syndrome is a unique disease with regard to presentation, response to treatment and survival. It remains to further identify strategies for risk stratification in treatment for these patients.nor
dc.description.abstractAbstract Background: Children with Down syndrome (DS) have an increased susceptibility for acute myeloid leukaemia (AML) related to mutations in the hematopoietic transcription factor GATA1. We wanted to explore AML in these children and describe its features with regard to patient characteristics and laboratory findings at diagnosis, the course before diagnosis, treatment response and follow-up status. Material and methods: We retrospectively identified all children with Down syndrome and AML treated at Oslo University Hospital in the period 1984-2013 (n=21) and compared these to the last registered non-DS children with AML (n=21) treated in the same hospital in the period 2002-2013. Data about patient characteristics, findings, symptoms, treatment and survival was collected from patient records and the Nordic society of haematology and oncology (NOPHO) database. Results: The patients in the DS-group were younger at the time of diagnosis (median age 1 year in DS-group vs. 7 years in non-DS-group), presented with lower values of leukocytes (median value 8,9 x109/l vs. 19,4 x109/l) and thrombocytes (median value 29,5 x109/l vs. 45 x109/l), and had a predominance of megakaryocytic leukaemia (90,5% vs. 4,8%). The DS-group had a longer median delay before diagnosis (95,5 days vs. 51 days) and had more bone marrow examinations (median value 2 vs. 1). The DS-children responded better to therapy with no relapses (0% vs. 42,9%) and better overall survival (86% vs 70%). Conclusions: Acute myeloid leukaemia in Down syndrome is a unique disease with regard to presentation, response to treatment and survival. It remains to further identify strategies for risk stratification in treatment for these patients.eng
dc.language.isonor
dc.subjectdowns
dc.subjectsyndrom
dc.subjectmyelogen
dc.subjectleukemi
dc.subjectmegakaryoblastisk
dc.titleAkutt myelogen leukemi hos barn med Downs syndromnor
dc.titleAcute myeloid leukemia in children with Downs syndromeeng
dc.typeMaster thesis
dc.date.updated2015-09-16T22:01:15Z
dc.creator.authorHagtvedt, Heidi Marthea Runningen
dc.identifier.urnURN:NBN:no-50199
dc.type.documentProsjektoppgave
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/45987/1/Akutt-myelogen-leukemi-hos-barn-med-Downs-syndrom-ferdig2.pdf


Files in this item

Appears in the following Collection

Hide metadata